Cargando…

Advances in cancer research. Volume 60 /

ADVANCES IN CANCER RESEARCH, VOLUME 60.

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Vande Woude, George F.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York : Academic Press, 1992.
Colección:Advances in cancer research ; v. 60
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Ma 4500
001 SCIDIR_ocn646754471
003 OCoLC
005 20231117033214.0
006 m o d
007 cr cn|||||||||
008 750720s1992 nyua ob 001 0 eng d
010 |z  52013360  
040 |a E7B  |b eng  |e pn  |c E7B  |d OCLCQ  |d UBY  |d OCLCQ  |d OPELS  |d OCLCQ  |d OCLCF  |d N$T  |d IDEBK  |d YDXCP  |d OCLCQ  |d DEBSZ  |d LEAUB  |d VLY  |d INARC  |d OCLCO  |d OCLCQ 
019 |a 261335525  |a 505089875  |a 906925460  |a 1162012721  |a 1397462837 
020 |a 0120066602  |q (electronic bk.) 
020 |a 9780120066605  |q (electronic bk.) 
020 |a 9780080562421  |q (electronic bk.) 
020 |a 0080562426  |q (electronic bk.) 
020 |a 1281409251 
020 |a 9781281409256 
020 |a 9786611409258 
020 |a 6611409254 
035 |a (OCoLC)646754471  |z (OCoLC)261335525  |z (OCoLC)505089875  |z (OCoLC)906925460  |z (OCoLC)1162012721  |z (OCoLC)1397462837 
050 4 |a RC267  |b .A4560 1992eb 
072 7 |a MED  |x 062000  |2 bisacsh 
072 7 |a HEA  |x 039030  |2 bisacsh 
082 0 4 |a 616.9940072  |2 22 
096 |a QZ 206  |f ADV 
245 0 0 |a Advances in cancer research.  |n Volume 60 /  |c edited by George Vande Woude. 
260 |a New York :  |b Academic Press,  |c 1992. 
300 |a 1 online resource (312 pages) :  |b illustrations. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 0 |a Advances in cancer research ;  |v v. 60 
504 |a Includes bibliographical references and index. 
588 0 |a Print version record. 
505 0 |a Front Cover; Advances in Cancer Research, Volume 60; Copyright Page; Contents; Contributors; Chapter 1. Structural and Functional Diversity in the FGF Receptor Multigene Family; I. Introduction; II. The FGF Family of Polypeptide Mitogens; III. Early Binding and Cross-Linking Studies of the FGF Receptor; IV. Nomenclature of the FGF Receptor Genes; V. Purification, cDNA Cloning, and Characterization of FGFR 1; VI. Characterization of EFGR 2, FGFR 3, and FGFR 4; VII. Multiple Forms of FGFR 1 and FGFR 2 Are Generated by Alternative Splicing; VIII. Multiple Forms of FGFR 1 
505 8 |a IX. Multiple Forms of FGFR 2X. FGFR 3 and FGFR 4; XI. Ligand Binding Specificities of the Cloned FGF Receptors; XII. Alternative Splicing in the Third Ig Domain Is Important for Determining Ligand Binding Specificities; XIII. Analogous Splice Variants from Different FGF Receptor Genes Encode Receptor Forms with Different Ligand Binding Specificities; XIV. Regulation of FGF Receptor Expression; XV. Cell- and Tissue-Specific Alternative Splicing of FGF Receptor mRNAs; XVI. Differential, Tissue-Specific Expression of the Different ' FGF Receptor Genes; XVII. The Drosophila FGF Receptor 
505 8 |a XVIII. FGF Receptor-Mediated Signal TransductionXIX. Concluding Remarks; References; Chapter 2. Protein Tyrosine Kinase Growth Factor Receptors and Their Ligands in Development, Differentiation, and Cancer; I. Introduction; II. Structure of Receptor Protein Tyrosine Kinases; III. RTKs in Development; IV. RTKs and Tumorigenesis; V. Genetics and Cancer; Reference; Chapter 3. The Molecular and Genetic Characterization of Human Soft Tissue Tumors; I. Introduction; II. Tumor Etiology; III. Genetic Susceptibility to Soft Tissue Tumors; IV. Detection of ras Gene Activation 
505 8 |a V. Chromosomal AbnormalitiesVI. Tumor Suppressor Genes; VII. Gene Amplification; VIII. Predictors of Tumor Behavior; IX. Molecular Cloning of Translocation Breakpoints; X. Future Developments; Reference; Note Added in Proof; Chapter 4. Genomic instability and Tumor Progression: Mechanistic Considerations; I. Introduction; II. Genomic Stability and Instability: Background and Implications; III. Mechanisms of Genomic Stability and Instability; IV. Quantitative Considerations; V. Summary and Perspectives; References; Chapter 5. Function and Regulation of the Human Multidrug Resistance Gene 
505 8 |a I. The Multidrug Transporter as a Cause of Multidrug ResistanceII. Regulation of Expression of mdr Genes; III. Summary and Conclusions; Reference; Chapter 6. Relationship between MYC Oncogene Activation and MHC Class I Expression; I. Introduction; II. MHC Class I Expression and Cancer; III. Modulation of MHC Class I Expression by Oncogences; IV. Molecular Mechanism of MHC Class I Regulation by Oncogenes; V. Biological Consequences of MHC Class I Downmodulation by Oncogenes; VI. Concluding Remarks; References; Chapter 7. Immunosuppressive Factors in Human Cancer; I. Introduction 
520 |a ADVANCES IN CANCER RESEARCH, VOLUME 60. 
546 |a English. 
650 0 |a Cancer  |x Research. 
650 0 |a Oncology, Experimental. 
650 2 |a Neoplasms, Experimental  |0 (DNLM)D009374 
650 6 |a Cancer  |x Recherche.  |0 (CaQQLa)201-0004697 
650 6 |a Canc�erologie exp�erimentale.  |0 (CaQQLa)201-0049886 
650 7 |a MEDICAL  |x Oncology.  |2 bisacsh 
650 7 |a HEALTH & FITNESS  |x Diseases  |x Cancer.  |2 bisacsh 
650 7 |a Cancer  |x Research.  |2 fast  |0 (OCoLC)fst00845497 
650 7 |a Oncology, Experimental.  |2 fast  |0 (OCoLC)fst01045747 
700 1 |a Vande Woude, George F. 
776 0 8 |i Print version:  |t Advances in cancer research. Volume 60.  |d New York : Academic Press, 1992  |w (DLC) 52013360 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/book/9780120066605  |z Texto completo